A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study Of Nivolumabversus Placebo In Combination With Neoadjuvant Chemotherapy And Adjuvant Endocrine Therapy In Patients With High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermalgrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer